ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Comparative evaluation of BacT/ALERT PF Plus and PF pediatric blood culture bottles: A dual in vitro and clinical retrospective study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposePrompt diagnosis of pediatric bloodstream infections (BSI) is challenged by low blood volumes and prior antibiotic use. This study systematically evaluated the performance of the new-generation BacT/ALERT PF Plus pediatric blood culture bottle against the standard PF bottle.
methodsThis study combined in vitro verification using 16 common BSI pathogens to compare time to detection (TTD) and antibiotic neutralization, with a retrospective clinical study of 10,920 pediatric blood cultures from 2019 to 2024.
resultsIn vitro, PF Plus bottles reduced median TTD by 2.39 h (P < 0.05) and demonstrated superior neutralization of ampicillin and vancomycin. Clinically, the transition to PF Plus increased the overall positivity rate (1.97% to 2.27%), significantly reduced median TTD by 4.06 h (P < 0.05), and expanded the pathogen spectrum to include key organisms like Staphylococcus aureus and non-fermenting bacteria. Blood volume analysis suggested a potential optimal range of 5.1-6.0 mL, while maintaining reliable performance at suboptimal volumes (< 1.0 mL).
conclusionThe PF Plus bottle offers faster detection, enhanced antibiotic neutralization, and improved pathogen recovery. Despite limitations inherent to retrospective designs, our data support PF Plus as an enhanced diagnostic tool and provide preliminary reference values for pediatric blood sample volumes.
Indexed as
Identifiers
41718916What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.